Results 31 to 40 of about 36,129 (239)

Uveitis occurring in a patient with psoriasis during adalimumab therapy: A case report

open access: yesIndian Journal of Dermatology, 2022
Here we report a case of a 34-year-old patient with psoriasis who developed uveitis induced by adalimumab. After receiving two subcutaneous injections of adalimumab, the patient suffered from a sudden onset of ocular pain and blurred vision in her left ...
Qiaoli Zheng   +3 more
doaj   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho   +4 more
wiley   +1 more source

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

open access: yesArthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi   +10 more
wiley   +1 more source

Spatial‐hindrance‐based pro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy

open access: yesBioengineering & Translational Medicine
Adalimumab (Humira) represents a major advance in rheumatoid arthritis (RA) therapy. However, with long‐term administration of Adalimumab, anti‐idiotypic antibody (anti‐Id Ab) accelerates the Adalimumab clearance rate and reduces the therapeutic effect ...
Bo‐Cheng Huang   +13 more
doaj   +1 more source

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

open access: yesVaccines, 2022
Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis.
Paolo Gisondi   +5 more
doaj   +1 more source

Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting. [PDF]

open access: yesClin Pharmacol Ther
Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into ...
Stojanovic D   +3 more
europepmc   +2 more sources

Multi‐Technique Integration Identifies O‐GlcNAc Transferase in Fibroblast‐Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis

open access: yesAdvanced Science, EarlyView.
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie   +14 more
wiley   +1 more source

Upadacitinib Restrains the Pathogenic Fitness of CD4+ T Cells and Aberrant B Cell Programming in Optic Neuritis

open access: yesAdvanced Science, EarlyView.
Single‐cell profiling and functional perturbation reveal coordinated JAK1‐pSTAT3 downstream programs in optic neuritis, including MCL1‐dependent fitness of pathogenic CD4+ Tem cells and glycolysis‐linked, cholesterol‐sensitive B‐cell responses associated with RORA. Upadacitinib disrupts this reciprocal T‐B‐cell circuit and alleviates neuroinflammation,
Gengchen Jiang   +12 more
wiley   +1 more source

Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis

open access: yesJAMA Dermatology
ImportanceIt is unclear whether concomitant methotrexate enhances the effectiveness and persistence of adalimumab for psoriasis. The recent OPTIMAP randomized clinical trial that tested adalimumab against adalimumab with methotrexate could not adequately answer this question due to underrecruitment.ObjectiveTo determine the effectiveness of using ...
Yiu, Zenas Z N   +5 more
openaire   +3 more sources

SensEnhance: A Genetic Circuit for Converting Endogenous Mammalian Gene Signals Into High‐Dynamic‐Range Genetic Readouts

open access: yesAdvanced Science, EarlyView.
Here, we present SensEnhance, a modular genetic circuit that converts leaky, low‐dynamic‐range promoter signals into tightly controlled, high‐dynamic‐range outputs. Applied to mechanosensing and IL‐6‐responsive promoters, SensEnhance increases fold changes from 2.6‐ and 2.5‐fold in promoter‐only configurations to over 20‐ and 14‐fold, respectively ...
Miguel Baños   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy